News Archive
Cantargia shows in-vivo proof of concept in malignant melanoma »
12-02-09
More attention on Cantargia in the internationally recognized magazine "BioCentury" »
12-01-31
ProNoxis has secured SEK 4.0 million in a new round of financing »
12-01-25
New rights issue in LU Bio February 2012 »
12-01-18
LUIS - LU Bio collaboration generates two new companies »
11-08-30
New investment in ProNoxis »
11-06-17
Attention on XImmune in BioCentury »
11-04-13
Cantargia builds power »
11-02-21
Continued progress in XImmune »
11-02-07
LU Bio acknowledged in high profile publication SciBX »
11-01-22
LU Bio sales of holdings »
10-12-08
Report on LU Bio portfolio company ProNoxis published in BioCentury »
10-10-07
LU Bio has decided to close the portfolio company Auril »
10-09-30
Article on Cantargia published in SciBX regarding “Homing in on CML stem cells“ »
10-09-17
LU Bio and Bio-Medisinsk Innovasjon AS in Oslo starts new co-operation »
10-09-13
LU Bio portfolio company Cantargia in the newsroom »
10-08-31
LU Bio dispose Oncorel holdings »
10-04-14
LU Bio portfolio company XImmune in the newsroom »
10-03-25
Dermagen reports successful phase I/IIa clinical trial »
09-12-02
LU Bioscience increases position in ProNoxis »
09-11-12
Successful findings from our portfolio company Auril noticed »
09-09-07
New investment dealing with temperature reduction in patients »
09-06-23
LU Bio announces a continued investment in Cytoguide ApS »
09-06-02
New portfolio company ProNoxis established »
09-06-01
Open seminar at Biomedical Center, Lund University, on March 25 »
09-03-15

More attention on Cantargia in the internationally recognized magazine "BioCentury"

Share
| Print |
Tell a colleague

Tell a colleague about this

Your name
Recipient E-mail

Share this page

LinkedIn
Windows Live
Facebook
Google Bookmarks
del.icio.us
digg
FriendFeed
MySpace

Click here to read the full BioCentury article about Cantargia

BioCentury is internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.

                                

                                


+46 (0)46 286 48 20
info@lubio.se
Ideon, Alfa 5
SE 223 70 Lund, Sweden
Lund University Bioscience AB
Contact us